

ASX ANNOUNCEMENT

Share placement of \$500,000 to cornerstone investor

27th July 2016: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, is pleased to announce the further placement of new fully paid ordinary shares to our American Virgin Islands cornerstone investor INOV8 LLC.

Shares will be issued in 2 tranches at an issue price of \$0.007 per share. The first tranche is for 35,714,285 shares with a settlement date of 31st August 2016. The second tranche is for 35,714,286 shares and settlement on the 30th September 2016. These allotments total \$500,000.

These funds, together with anticipated R & D tax incentive for 2016 and the expenditure reduction program, strengthens Analytica's cash position. Analytica continues to execute its development strategy of:

- Building best in class,
- Gathering evidence to show the product works,
- Proving market acceptance, and
- Negotiating a partnership with a corporation with the resources to commercialise across the world.

"INOV8 LLC increasing their investment expresses confidence in the potential of the PeriCoach system and our strategic development program" said Dr Monsour, Analytica Chairman. "This investment, building INOV8's holding to 12.2%, together with the strong support from major shareholder placements earlier this year adds to the stability of Analytica's capital base."

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:    

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

